Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis

@article{Harada2010DienogestAN,
  title={Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis},
  author={Tasuku Harada and Fuminori Taniguchi},
  journal={Women's Health},
  year={2010},
  volume={6},
  pages={27 - 35}
}
Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors. Owing to its antiovulatory, antiproliferative activities in endometrial cells, and its inhibitory effects on the secretion of cytokines, DNG is expected to be an effective treatment for endometriosis. Progesterone receptor-binding affinity is higher for DNG than for progesterone. Several pilot studies demonstrated that after 24 weeks of DNG treatment… 
View on SAGE
doi.org
65 Citations
Highly Influential Citations
1
Background Citations
27
Methods Citations
6
Results Citations
1

Tables from this paper

65 Citations

Dienogest: an oral progestogen for the treatment of endometriosis
TLDR
Clinical experience of dienogest at 2 mg daily orally demonstrates that it significantly reduces endometriotic lesions and provides effective pain relief comparable to the current efficacy standard, combined with a favorable safety and tolerability profile that allows long-term use.
Dienogest (DNG) in der Therapie der Endometriose
TLDR
Dienogest (DNG) seems to offer an effective long-term therapy option for patients with acceptable quality of life, but it should be kept in mind that DNG is not the end of the efforts to discover innovative approaches in cause and treatment of endometriosis.
Dienogest: an oral progestogen for the treatment
TLDR
Clinical experience of dienogest at 2 mg daily orally demonstrates that it significantly reduces endometriotic lesions and provides effective pain relief comparable to the current efficacy standard, combined with a favorable safety and tolerability profile that allows long ‑ term use.
Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma
TLDR
Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.
Progestins for the Treatment of Endometriosis: An Update
TLDR
A progestin called dienogest, recently introduced for the treatment of endometriosis, will be given special focus, describing its mechanism of action and clinical results.
Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data
TLDR
DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometRIosis.
Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis
TLDR
This review aims to offer the reader a complete overview of pharmacokinetic (PK) and clinical efficacy of progestins for the treatment of endometriosis.
Comparison of dienogest effects upon 3,3'-diindolylmethane supplementation in models of endometriosis and clinical cases.
Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
TLDR
Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time and is expected to be clinically applicable as a new drug for the treatment of endometrial cancer.
Current and Emerging Therapeutics for the Management of Endometriosis
TLDR
Because few data are available on long-term efficacy and safety of aromatase inhibitors they should be administered only in women with symptoms refractory to other conventional therapies in a clinical research setting.
...
...

References

SHOWING 1-10 OF 38 REFERENCES
High-dose pilot study with the novel progestogen dienogestin patients with endometriosis
TLDR
Long-term high-dose dienogest therapy can be recommended particularly for women with progressive endometriosis, as neither the menopausal symptoms caused by therapy with gonadotropin-releasing hormone agonists nor the adverse androgen-related effects induced by danazol were observed.
Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid.
TLDR
The findings suggest that dienogest is not a pure progestin and appears to induce fewer side effects than drugs currently on the market for the treatment of endometriosis.
The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro.
TLDR
Data imply that dienogest exerts direct effect in suppressing growth of endometriotic implants, and directly acts on endometrial tissue in progestogenic response, such as decidualization, increased prolactin production and growth retardation.
Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial.
Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study.
Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.
TLDR
Both the LNG-IUS and the GnRH-analogue were effective in the treatment of CPP-associated endometriosis, although no differences were observed between the two treatments.
Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys
TLDR
Results indicate that the induction of atresia of the ovarian dominant follicle by direct action would be a possible mechanism of dienogest to inhibit plasma E2 level.
Endometriosis: aetiology, pathogenesis and treatment.
TLDR
There is little difference in efficacy between the different medications but their adverse effect profiles differ greatly, and it appears that gonadotropin-releasing hormone agonists, particularly when used with add-back estrogen, may be more acceptable to women than other treatments.
Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells.
Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study
...
...